<!DOCTYPE html>
<html lang="en">
<head>
 <meta charset="UTF-8">
 <meta name="viewport" content="width=device-width, initial-scale=1.0">
 <title>Lesson 20.2: Objective Bio-Markers and Emerging Diagnostics | AccrediPro Academy</title>
 <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
 <style>
/* ===========================================
 ACCREDIPRO GOLD STANDARD - UNIFIED LESSON CSS v5.0
 School-Quality ‚Ä¢ ASI Certified ‚Ä¢ Premium UX
 =========================================== */

/* Reset & Base */
* {
 box-sizing: border-box;
 margin: 0;
 padding: 0;
}

body {
 font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
 line-height: 1.8;
 color: #1f2937;
 background: #ffffff;
 font-size: 17px;
}

/* MAIN WRAPPER */
.lesson-wrapper {
 max-width: 1200px;
 margin: 0 auto;
 padding: 40px 20px;
}

/* HEADER CARD - Premium Gradient */
.module-header-card {
 background: linear-gradient(135deg, #722F37 0%, #722F37 50%, #5a252b 100%);
 padding: 48px 40px;
 margin-bottom: 40px;
 border-radius: 24px;
 box-shadow: 0 20px 60px -15px rgba(114, 47, 55, 0.4);
 border: none;
 text-align: center;
 position: relative;
 overflow: hidden;
}

.module-header-card::before {
 content: '';
 position: absolute;
 top: -50%;
 left: -50%;
 width: 200%;
 height: 200%;
 background: radial-gradient(circle, rgba(255, 255, 255, 0.05) 0%, transparent 70%);
 pointer-events: none;
}

.module-label {
 font-size: 12px;
 text-transform: uppercase;
 letter-spacing: 3px;
 color: rgba(255, 255, 255, 0.8);
 margin-bottom: 12px;
 font-weight: 600;
 display: block;
}

.lesson-title {
 font-size: 38px;
 color: #ffffff;
 font-weight: 800;
 margin: 0 0 20px 0;
 line-height: 1.15;
 text-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
}

/* META BADGES */
.lesson-meta {
 display: flex;
 justify-content: center;
 gap: 12px;
 flex-wrap: wrap;
}

.meta-badge {
 background: rgba(255, 255, 255, 0.15);
 color: white;
 padding: 8px 18px;
 border-radius: 24px;
 font-size: 13px;
 font-weight: 600;
 backdrop-filter: blur(8px);
 display: flex;
 align-items: center;
 gap: 6px;
}

/* ASI CREDENTIAL STRIP */
.asi-credential-strip {
 background: linear-gradient(90deg, #f8f5f0, #fffbeb, #f8f5f0);
 border: 1px solid #e5d9c3;
 border-radius: 12px;
 padding: 16px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.asi-logo {
 width: 48px;
 height: 48px;
 background: linear-gradient(135deg, #B8860B, #D4A813);
 border-radius: 10px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
 color: white;
 flex-shrink: 0;
 box-shadow: 0 4px 12px rgba(184, 134, 11, 0.25);
}

.asi-text {
 flex: 1;
}

.asi-text .label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1px;
 color: #92400e;
 font-weight: 700;
}

.asi-text .title {
 font-size: 15px;
 color: #78350f;
 font-weight: 600;
 margin-top: 2px;
}

/* TABLE OF CONTENTS */
.toc-box {
 background: transparent;
 border: none;
 padding: 0;
 margin-bottom: 40px;
}

.toc-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #6b7280;
 font-weight: 700;
 margin-bottom: 16px;
 display: block;
}

.toc-list {
 list-style: none;
 display: grid;
 grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
 gap: 8px;
}

.toc-list li a {
 display: flex;
 align-items: center;
 gap: 10px;
 padding: 10px 14px;
 background: #f9fafb;
 border-radius: 8px;
 text-decoration: none;
 color: #374151;
 font-size: 14px;
 font-weight: 500;
 transition: all 0.2s;
}

.toc-list li a:hover {
 background: #fdf2f4;
 color: #722F37;
 transform: translateX(4px);
}

.section-num {
 background: #722F37;
 color: white;
 width: 24px;
 height: 24px;
 border-radius: 6px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 11px;
 font-weight: 700;
 flex-shrink: 0;
}

/* WELCOME BOX */
.welcome-box {
 background: linear-gradient(135deg, #fefbf3 0%, #f8f5f0 100%);
 padding: 28px;
 margin-bottom: 40px;
 border-radius: 16px;
 border-left: 5px solid #B8860B;
 box-shadow: 0 4px 12px rgba(0, 0, 0, 0.04);
}

/* OBJECTIVES BOX */
.objectives-box {
 background: #fdf2f4;
 border-radius: 16px;
 padding: 28px;
 margin-bottom: 40px;
 border: 1px solid #722F37;
}

.box-label {
 font-weight: 700;
 color: #722F37;
 text-transform: uppercase;
 letter-spacing: 1px;
 font-size: 12px;
 margin-bottom: 16px;
 display: block;
}

.objectives-box ul {
 list-style: none;
 margin: 0;
 padding: 0;
}

.objectives-box li {
 padding: 10px 0 10px 32px;
 position: relative;
 font-size: 16px;
 color: #1f2937;
}

.objectives-box li::before {
 content: '‚úì';
 position: absolute;
 left: 0;
 color: #722F37;
 font-weight: 700;
}

/* TYPOGRAPHY */
h2 {
 color: #722F37;
 font-size: 28px;
 margin: 56px 0 24px 0;
 font-weight: 800;
 position: relative;
 padding-bottom: 16px;
}

h2::after {
 content: '';
 position: absolute;
 bottom: 0;
 left: 0;
 width: 60px;
 height: 4px;
 background: linear-gradient(90deg, #B8860B, #D4A813);
 border-radius: 2px;
}

h3 {
 color: #722F37;
 font-size: 22px;
 margin: 36px 0 16px 0;
 font-weight: 700;
}

.highlight {
 background: linear-gradient(120deg, #fef3c7 0%, #fef3c7 100%);
 padding: 1px 6px;
 border-radius: 4px;
 font-weight: 600;
 color: inherit;
}

/* CASE STUDY */
.case-study {
 background: white;
 border-radius: 20px;
 margin: 40px 0;
 border: 1px solid #e5e7eb;
 border-left: 6px solid #722F37;
 box-shadow: 0 8px 30px rgba(0, 0, 0, 0.06);
 overflow: hidden;
}

.case-study-header {
 background: #fdf2f4;
 padding: 20px 28px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.case-study-content {
 padding: 28px;
}

/* DATA TABLE */
.data-table {
 width: 100%;
 border-collapse: collapse;
 margin: 25px 0;
 font-size: 15px;
}

.data-table th {
 background: #722F37;
 color: white;
 padding: 12px 15px;
 text-align: left;
}

.data-table td {
 padding: 12px 15px;
 border-bottom: 1px solid #e5e7eb;
}

.data-table tr:nth-child(even) {
 background: #f9fafb;
}

/* COACH TIP */
.coach-tip {
 background: linear-gradient(135deg, #fefce8 0%, #fef9c3 100%);
 border: 1px solid #fde047;
 border-radius: 16px;
 padding: 24px 28px;
 margin: 32px 0;
 position: relative;
}

.coach-tip .tip-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #a16207;
 font-weight: 700;
 margin-bottom: 8px;
 display: block;
}

/* CHECK UNDERSTANDING */
.check-understanding {
 background: #fdfbf7;
 border: 2px solid #B8860B;
 border-radius: 16px;
 padding: 35px;
 margin: 50px 0;
}

.check-understanding .box-label {
 font-weight: 700;
 color: #8B6914;
 margin-bottom: 25px;
 font-size: 14px;
 text-transform: uppercase;
 letter-spacing: 2px;
 text-align: center;
}

.question-item {
 background: white;
 padding: 25px;
 border-radius: 12px;
 margin-bottom: 20px;
 border: 1px solid #e5e7eb;
}

.reveal-btn {
 background: #722F37;
 color: white;
 border: none;
 padding: 12px 24px;
 border-radius: 8px;
 cursor: pointer;
 font-weight: 600;
 margin-top: 15px;
}

.answer-text {
 display: none;
 margin-top: 20px;
 padding: 20px;
 background: #fdf2f4;
 border-radius: 8px;
 color: #722F37;
 font-size: 16px;
 border-left: 4px solid #722F37;
}

/* TAKEAWAYS BOX */
.takeaways-box {
 background: #722F37;
 color: #ffffff;
 padding: 35px;
 border-radius: 16px;
 margin-top: 60px;
}

.takeaways-box .box-label {
 color: #B8860B;
 font-weight: 700;
 margin-bottom: 20px;
 text-transform: uppercase;
 letter-spacing: 2px;
 font-size: 14px;
}

.takeaways-box ul {
 margin: 0;
 padding-left: 20px;
}

.takeaways-box li {
 margin-bottom: 12px;
 color: #ffffff;
}

/* REFERENCES BOX */
.references-box {
 background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
 border: 1px solid #e2e8f0;
 border-radius: 16px;
 padding: 28px 32px;
 margin-top: 48px;
}

.references-box ol {
 padding-left: 20px;
}

.references-box li {
 font-size: 14px;
 margin-bottom: 10px;
 color: #475569;
}

/* STAT HIGHLIGHT */
.stat-highlight {
 font-weight: 800;
 color: #722F37;
}

.module-connection {
 background: #f0f9ff;
 border: 1px solid #7dd3fc;
 border-radius: 16px;
 padding: 20px 24px;
 margin-bottom: 32px;
}
 </style>
</head>
<body>

<div class="lesson-wrapper">
 <!-- Module Header Card -->
 <div class="module-header-card">
 <span class="module-label">Module 20: Assessment Tools</span>
 <h1 class="lesson-title">Objective Bio-Markers and Emerging Diagnostics</h1>
 <div class="lesson-meta">
 <span class="meta-badge">Lesson 2 of 8</span>
 <span class="meta-badge">‚è±Ô∏è 15 min read</span>
 <span class="meta-badge">ASI Certified</span>
 </div>
 </div>

 <!-- ASI Credential Strip -->
 <div class="asi-credential-strip">
 <div class="asi-logo">ASI</div>
 <div class="asi-text">
 <div class="label">Credential Verification</div>
 <div class="title">AccrediPro Standards Institute Verified Content</div>
 </div>
 </div>

 <!-- Table of Contents -->
 <nav class="toc-box">
 <p class="toc-label">Lesson Navigation</p>
 <ul class="toc-list">
 <li><a href="#fma-test"><span class="section-num">01</span>The FM/a¬Æ Test</a></li>
 <li><a href="#sfn-assessment"><span class="section-num">02</span>Small Fiber Neuropathy</a></li>
 <li><a href="#neuroimaging"><span class="section-num">03</span>Neuroimaging Insights</a></li>
 <li><a href="#csf-markers"><span class="section-num">04</span>CSF Bio-Markers</a></li>
 <li><a href="#mitochondria"><span class="section-num">05</span>Mitochondrial Function</a></li>
 </ul>
 </nav>

 <!-- Module Connection -->
 <div class="module-connection">
 <p>In Lesson 1, we mastered the <strong>WPI</strong> and <strong>SSS</strong> clinical metrics. While those remain the gold standard for diagnosis, Lesson 2 bridges the gap between patient report and <span class="highlight">biological reality</span>, providing the objective data needed to silence skeptics and refine the <strong>R.E.S.T.O.R.E. Framework‚Ñ¢</strong>.</p>
 </div>

 <!-- Welcome Box -->
 <div class="welcome-box">
 <p>For decades, Fibromyalgia was labeled a "diagnosis of exclusion" or, worse, a psychosomatic disorder. Today, we are entering the era of <strong>Precision Fibromyalgia Care</strong>. This lesson equips you with the knowledge of emerging diagnostic tools that provide objective proof of Central Sensitization and immunological dysfunction. Understanding these markers allows you to validate your clients' experiences with hard science.</p>
 </div>

 <!-- Learning Objectives -->
 <div class="objectives-box">
 <p class="box-label">Learning Objectives</p>
 <ul>
 <li>Analyze the mechanism of the FM/a¬Æ Test and its 93% sensitivity in identifying immunological markers.</li>
 <li>Evaluate the clinical utility of skin punch biopsies in diagnosing comorbid Small Fiber Neuropathy (SFN).</li>
 <li>Interpret fMRI and PET scan data regarding neuro-connectivity and gray matter changes.</li>
 <li>Identify the roles of Substance P and Glutamate in cerebrospinal fluid as indicators of CNS overdrive.</li>
 <li>Determine the validity of mitochondrial function testing in chronic fatigue phenotypes.</li>
 </ul>
 </div>

 <!-- Case Study 1 -->
 <div class="case-study">
 <div class="case-study-header">
 <div class="case-study-icon">üî¨</div>
 <div>
 <p class="title">Case Study: Validation Through Data</p>
 <p class="subtitle">Sarah, 52, Former Registered Nurse</p>
 </div>
 </div>
 <div class="case-study-content">
 <p><strong>Presenting Symptoms:</strong> Sarah left her nursing career due to "invisible" pain and brain fog. Despite high WPI scores, her family physician suggested her symptoms were "stress-related" due to menopause. This led to significant <span class="highlight">imposter syndrome</span> and a lack of treatment compliance.</p>
 <p><strong>Intervention:</strong> Sarah sought a specialist who ordered the <strong>FM/a¬Æ Test</strong> and a <strong>skin punch biopsy</strong>.</p>
 <p><strong>Outcomes:</strong> Sarah's FM/a score was 94/100, and her biopsy showed a significant reduction in intraepidermal nerve fiber density (IENFD). The objective proof shifted her mindset from "Am I crazy?" to "I have a biological neuro-immune condition." This psychological shift accelerated her adherence to the <strong>R.E.S.T.O.R.E. Framework‚Ñ¢</strong> pacing protocols.</p>
 </div>
 </div>

 <h2 id="fma-test">Analyzing the FM/a¬Æ Test: The Immunological Signature</h2>
 <p>The <strong>FM/a¬Æ Test</strong>, developed by EpicGenetics, represents a paradigm shift in Fibromyalgia diagnostics. Rather than relying on pain reports, it measures the concentration of specific <strong>cytokines</strong> and <strong>chemokines</strong> in peripheral blood mononuclear cells (PBMCs).</p>
 
 <p>A 2015 study demonstrated that Fibromyalgia patients exhibit a unique immunological profile characterized by a <span class="highlight">blunted cytokine response</span> when their immune cells are challenged. Specifically, the test looks at:</p>
 
 <table class="data-table">
 <thead>
 <tr>
 <th>Marker Category</th>
 <th>Specific Markers</th>
 <th>Clinical Significance</th>
 </tr>
 </thead>
 <tbody>
 <tr>
 <td><strong>Pro-inflammatory Chemokines</strong></td>
 <td>MCP-1, MIP-1Œ±, MIP-1Œ≤</td>
 <td>Indicates recruitment of immune cells to the CNS.</td>
 </tr>
 <tr>
 <td><strong>Cytokines</strong></td>
 <td>IL-6, IL-8</td>
 <td>Associated with pain intensity and sleep disturbances.</td>
 </tr>
 <tr>
 <td><strong>Immune Response</strong></td>
 <td>PBMC protein levels</td>
 <td>Differentiates FM from RA or Lupus with high specificity.</td>
 </tr>
 </tbody>
 </table>

 <p>The test produces a score from 1 to 100. A score <span class="stat-highlight">above 50</span> is considered positive for Fibromyalgia. With a reported <strong>sensitivity of 93%</strong>, it provides the "biological proof" many clients crave.</p>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip: The Power of Validation</span>
 <p>As a specialist, you may not order this test yourself, but being able to interpret the results for a client is a high-value skill. When a client sees a score of 85, their cortisol levels often drop simply because they no longer feel they have to "prove" they are sick. This is the first step in <strong>Overdrive Regulation</strong>.</p>
 </div>

 <h2 id="sfn-assessment">Small Fiber Neuropathy (SFN) and Skin Biopsy</h2>
 <p>Research suggests that up to <span class="stat-highlight">40% of patients</span> diagnosed with Fibromyalgia actually have <strong>Small Fiber Neuropathy (SFN)</strong>, or have it as a major comorbid driver of their pain. SFN involves damage to the small, unmyelinated C-fibers and thinly myelinated A-delta fibers that transmit pain and temperature signals.</p>

 <p>The gold standard for assessment is the <strong>3mm Skin Punch Biopsy</strong>, typically taken from the distal leg. Pathologists measure the <strong>Intraepidermal Nerve Fiber Density (IENFD)</strong>. A low density confirms that the pain has a peripheral, structural component, not just a central one.</p>

 <ul>
 <li><strong>Differential Diagnosis:</strong> If a client describes "burning," "stinging," or "electric shocks," SFN is highly likely.</li>
 <li><strong>Clinical Utility:</strong> SFN diagnosis may lead to different medical interventions (e.g., IVIG or specific neuropathic agents) and helps the Specialist tailor the <strong>Targeted Movement</strong> module to avoid nerve irritation.</li>
 </ul>

 <h2 id="neuroimaging">Neuroimaging Insights: The Brain's Pain Map</h2>
 <p>While fMRI and PET scans are not yet used for routine clinical diagnosis due to cost, they have been instrumental in proving the <strong>Neurobiology of Central Sensitization</strong>.</p>

 <h3>1. Functional MRI (fMRI)</h3>
 <p>fMRI studies show that FM patients exhibit <strong>hyper-connectivity</strong> within the <strong>Salience Network</strong> (which decides what stimuli deserve attention) and <strong>decreased connectivity</strong> in the <strong>Descending Pain Modulatory System</strong> (the body's internal pharmacy for pain relief).</p>

 <h3>2. Gray Matter Volume</h3>
 <p>Research indicates that chronic Fibromyalgia is associated with a <span class="highlight">premature loss of gray matter</span> (up to 9.5 times the rate of healthy aging) in the prefrontal cortex and anterior cingulate cortex‚Äîareas responsible for executive function and emotional regulation.</p>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip: Explaining "Fibro Fog"</span>
 <p>Use this data to explain "Fibro Fog" to your clients. Tell them: "Your brain's 'hardware' is working overtime to process pain signals, which leaves less 'RAM' for memory and focus. We aren't just managing pain; we are trying to preserve your brain's gray matter through neuroplasticity."</p>
 </div>

 <h2 id="csf-markers">Cerebrospinal Fluid (CSF) Analysis</h2>
 <p>Though invasive (requiring a lumbar puncture), CSF analysis has provided the most direct evidence of CNS dysfunction in FM. Two primary markers stand out:</p>

 <ol>
 <li><strong>Substance P:</strong> A neurotransmitter that amplifies pain signals. Studies consistently find Substance P levels in FM patients are <span class="stat-highlight">3x higher</span> than in healthy controls.</li>
 <li><strong>Glutamate:</strong> The primary excitatory neurotransmitter. Elevated levels in the insula correlate directly with higher pain sensitivity and lower pain thresholds.</li>
 </ol>

 <p>This "chemical soup" in the brain explains why Fibromyalgia patients feel pain from stimuli that others find neutral (allodynia).</p>

 <h2 id="mitochondria">Mitochondrial Function and ATP Production</h2>
 <p>Emerging diagnostics are focusing on the <strong>Bio-Energetic</strong> component of FM. Mitochondrial dysfunction is often the "root" of the <strong>Energy Pacing</strong> struggles explored in Module 2.</p>

 <p>Tests measuring <strong>CoQ10 levels</strong> in PBMCs and <strong>mitochondrial DNA (mtDNA)</strong> damage have shown that FM patients often have significantly reduced ATP production. This leads to a state of "metabolic bankruptcy," where the cells literally do not have the energy to perform basic repair functions, leading to oxidative stress and further pain.</p>

 <!-- Case Study 2 -->
 <div class="case-study">
 <div class="case-study-header">
 <div class="case-study-icon">‚ö°</div>
 <div>
 <p class="title">Case Study: Mitochondrial Mapping</p>
 <p class="subtitle">Elena, 45, High School Teacher</p>
 </div>
 </div>
 <div class="case-study-content">
 <p>Elena suffered from severe Post-Exertional Malaise (PEM). Her mitochondrial markers showed severe oxidative stress and low CoQ10. By identifying this <span class="highlight">objective bio-marker</span>, her specialist shifted her focus from "exercise" to "mitochondrial support" (Targeted Movement Lesson 3). Within 6 months of using this data-driven approach, Elena returned to part-time teaching, earning an additional <strong>$35,000/year</strong> she thought was gone forever.</p>
 </div>
 </div>

 <!-- Check Your Understanding -->
 <div class="check-understanding">
 <p class="box-label">Check Your Understanding</p>
 
 <div class="question-item">
 <p class="question-text"><strong>1. What is the reported sensitivity of the FM/a¬Æ Test in identifying Fibromyalgia?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">The FM/a¬Æ Test has a reported sensitivity of 93%.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>2. What percentage of Fibromyalgia patients are estimated to have comorbid Small Fiber Neuropathy (SFN)?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">Approximately 40% of patients diagnosed with FM show evidence of SFN via skin biopsy.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>3. Substance P levels in the cerebrospinal fluid of FM patients are typically how much higher than controls?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">Levels are typically 3 times (3x) higher than in healthy controls.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>4. Which neuroimaging finding is associated with "Fibro Fog" and executive dysfunction?</strong></p>
 <button class="reveal-btn">Reveal Answer</button>
 <div class="answer-text">The premature loss of gray matter volume in the prefrontal cortex and hyper-connectivity in the Salience Network.</div>
 </div>
 </div>

 <!-- Key Takeaways -->
 <div class="takeaways-box">
 <p class="box-label">Key Takeaways</p>
 <ul>
 <li><strong>Objective Evidence Exists:</strong> Fibromyalgia is no longer a "hidden" disease; it has clear immunological and neurological signatures.</li>
 <li><strong>The FM/a¬Æ Test:</strong> Provides a 93% sensitive blood-based marker using cytokine/chemokine patterns.</li>
 <li><strong>Peripheral vs. Central:</strong> Skin biopsies for SFN help differentiate between peripheral nerve damage and central sensitization.</li>
 <li><strong>Neuro-Metabolic Debt:</strong> Elevated Substance P and mitochondrial dysfunction provide a biological explanation for pain amplification and fatigue.</li>
 <li><strong>Specialist Role:</strong> Use these diagnostics to provide legitimacy, reduce client stress, and refine the R.E.S.T.O.R.E. Framework‚Ñ¢ interventions.</li>
 </ul>
 </div>

 <!-- References Box -->
 <div class="references-box">
 <p class="box-label">References & Further Reading</p>
 <ol>
 <li>Wallace, D. J., et al. (2015). "The FM/a test: A blood test for fibromyalgia." <em>BMC Musculoskeletal Disorders</em>.</li>
 <li>Oaklander, A. L., et al. (2013). "Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia." <em>Pain</em>.</li>
 <li>Gracely, R. H., et al. (2002). "Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia." <em>Arthritis & Rheumatism</em>.</li>
 <li>Russell, I. J., et al. (1994). "Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome." <em>Arthritis & Rheumatism</em>.</li>
 <li>Cordero, M. D., et al. (2010). "Mitochondrial dysfunction and mitophagy in fibromyalgia patients." <em>Free Radical Biology and Medicine</em>.</li>
 <li>Clauw, D. J. (2014). "Fibromyalgia: A Clinical Review." <em>JAMA</em>.</li>
 </ol>
 </div>
</div>

<script>
 document.querySelectorAll('.reveal-btn').forEach(button => {
 button.addEventListener('click', function() {
 const answer = this.nextElementSibling;
 if (answer && answer.classList.contains('answer-text')) {
 answer.classList.toggle('show');
 answer.style.display = answer.style.display === 'none' || answer.style.display === '' ? 'block' : 'none';
 }
 });
 });
</script>

</body>
</html>